Published in Clin Gastroenterol Hepatol on May 18, 2017
A flood of opioids, a rising tide of deaths. N Engl J Med (2010) 6.96
Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology (1992) 5.86
Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain (2004) 5.51
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA (1995) 5.05
Opioid complications and side effects. Pain Physician (2008) 4.24
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26
A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain (2008) 2.76
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol (2002) 2.76
Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg (2001) 2.63
Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain (1998) 2.52
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42
Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs (2003) 2.42
Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology (2010) 2.30
The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med (2008) 2.26
Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med (2014) 2.05
Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol (1993) 2.04
Mechanisms and treatment of postoperative ileus. Arch Surg (2003) 2.01
Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage (2002) 2.00
Constipation Prophylaxis Is Rare for Adults Prescribed Outpatient Opioid Therapy From U.S. Emergency Departments. Acad Emerg Med (2015) 2.00
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Function of opioids in the enteric nervous system. Neurogastroenterol Motil (2004) 1.84
Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med (2016) 1.82
Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother (2009) 1.75
The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol (2007) 1.60
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig (2010) 1.60
Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend (2006) 1.52
Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ (2009) 1.51
Effects of morphine on the human sphincter of Oddi. Gut (1988) 1.44
Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut (2001) 1.43
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother (2010) 1.42
Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci (1984) 1.41
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology (2013) 1.38
Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol (2005) 1.37
Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci (2001) 1.35
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol (2016) 1.32
Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett (2004) 1.30
Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage (2002) 1.28
The use of quaternary narcotic antagonists in opiate research. Neuropharmacology (1985) 1.27
Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract (2010) 1.25
Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther (2009) 1.23
Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil (2010) 1.23
Oral naloxone reverses opioid-associated constipation. Pain (2000) 1.20
Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience (1997) 1.18
Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology (1997) 1.17
Narcotic analgesic effects on the sphincter of Oddi: a review of the data and therapeutic implications in treating pancreatitis. Am J Gastroenterol (2001) 1.15
Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain (2011) 1.11
Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med (2009) 1.07
Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. Life Sci (1989) 1.07
Endogenous morphine. Trends Neurosci (2000) 1.07
Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am J Gastroenterol (2012) 1.06
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm (2003) 1.03
Retracted The fifth vital sign--what does it mean? Pain Pract (2008) 1.03
Kappa opioids and the modulation of pain. Psychopharmacology (Berl) (2010) 1.03
Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl (1987) 1.01
Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther (2002) 1.01
Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol (1997) 1.00
Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl (1987) 0.99
Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther (2014) 0.99
Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs (2011) 0.99
Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol Exp Ther (1987) 0.98
Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterol Motil (2013) 0.97
The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res (2011) 0.97
Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time. Pain Med (2015) 0.97
Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs (2014) 0.97
Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage (2010) 0.97
Molecular recognition of opioid receptor ligands. AAPS J (2006) 0.95
Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteria. Am J Gastroenterol (2011) 0.95
Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain (2010) 0.94
The role of tachykinin NK-1 receptors in the area postrema of ferrets in emesis. Neurosci Lett (2000) 0.93
Effects of meperidine on the pancreatic and biliary sphincter. Gastrointest Endosc (1996) 0.93
Effects of morphine and naloxone on esophageal motility and gastric emptying in man. Dig Dis Sci (1986) 0.93
Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol (2015) 0.92
Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids. Am J Gastroenterol (2015) 0.92
Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents. Cell Biochem Biophys (2013) 0.92
Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am J Gastroenterol (2009) 0.92
Opioid receptor desensitization: mechanisms and its link to tolerance. Front Pharmacol (2014) 0.91
The effect of loperamide on anorectal function in normal healthy men. J Clin Gastroenterol (1992) 0.91
Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl (2014) 0.91
Naloxone antagonizes narcotic self blockade of emesis in the cat. J Pharmacol Exp Ther (1977) 0.90
A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol (2015) 0.90
Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. Pain Med (2015) 0.89
On the role of extracellular loops of opioid receptors in conferring ligand selectivity. FEBS Lett (1995) 0.88
A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. Pain (2016) 0.87
Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. J Nucl Med (1996) 0.87
Dose-related effects of synthetic human beta-endorphin and naloxone on fed gastrointestinal motility. Am J Physiol (1986) 0.86
Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia. Gut (1993) 0.86
Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care (Engl) (2011) 0.86
Chronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol (2015) 0.85
Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther (1999) 0.84
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol (2012) 0.84
Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents. Am J Physiol Cell Physiol (2014) 0.83
A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Aliment Pharmacol Ther (2012) 0.83
A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med (2014) 0.83
Control mechanism of spontaneous in vitro contractions of the opossum sphincter of Oddi. Am J Physiol (1985) 0.83
Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health (2011) 0.83
The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl (2014) 0.82
Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol (1999) 0.82
A working paradigm for the treatment of obesity in gastrointestinal practice. Tech Gastrointest Endosc (2017) 0.77